CCCG-ALL 2015方案与CCLG-ALL 2008方案治疗儿童急性淋巴细胞白血病的早期疗效及严重不良事件对比  

Comparison of the Early Efficacy and Serious Adverse Events between CCCG-ALL 2015 and CCLG-ALL 2008 in the Treatment of Pediatric Patients with Acute Lymphoblastic Leukemia

作　　者：潘丽丽[1] 郑湧智 乐少华[1] 华雪玲[1] 郑浩[1] 陈再生[1] 李健[1] PAN Li-Li;ZHENG Yong-Zhi;LE Shao-Hua;HUA Xue-Ling;ZHENG Hao;CHEN Zai-Sheng;LI Jian(Department of Pediatric Hematology,Fujian Medical University Union Hospital,Fujian Institute of Hematology,Fujian Provincial Key Laboratory of Hematology,Fuzhou 350001,Fujian Province,China)

机构地区：[1]福建医科大学附属协和医院小儿血液科,福建省血液病研究所,福建省血液病学重点实验室,福建福州350001

出　　处：《中国实验血液学杂志》2022年第3期726-731,共6页Journal of Experimental Hematology

基　　金：福建省血液医学中心建设项目[闽政办(2017)4号];福建省卫生计生中青年骨干人才培养项目(2018-ZQN-26);福建医科大学启航基金项目(2019QH1032)。

摘　　要：目的:探讨不同方案治疗儿童急性淋巴细胞白血病(ALL)的早期疗效及严重不良事件(SAE),以进一步提高ALL患儿总体生存率。方法:对比2019年1月至2020年6月接受中国儿童肿瘤协作组-ALL 2015方案治疗(CCCG-ALL 2015方案组)与2017年1月至2018年12月接受中国儿童白血病协作组-ALL 2008方案治疗(CCLGALL 2008方案组)患儿的早期疗效和SAE。结果:两组患儿巩固化疗前完全缓解率差异无统计学意义(P=0.198),但微小残留病转阴率CCLG-ALL 2008方案组显著高于CCCG-ALL 2015方案组(P=0.000)。CCCG-ALL 2015方案组SAE发生率显著低于CCLG-ALL 2008方案组(P=0.021),且感染相关SAE发生率后者显著高于前者(P=0.001),而非感染相关SAE差异无统计学意义(P=0.623)。CCCG-ALL 2015方案组治疗相关死亡率显著低于CCLG-ALL 2008方案组(P=0.003)。结论:CCCG-ALL 2015方案降低了化疗的强度,能显著降低化疗相关SAE尤其是感染相关SAE的发生率,并降低治疗相关死亡率,但巩固治疗前微小残留病转阴率较低,总体远期疗效仍有待进一步随访观察。Objective: To evaluate the early efficacy and serious adverse events(SAE) related to chemotherapy of different protocols in the treatment of pediatric patients with acute lymphoblastic leukemia(ALL), so as to improve the overall survival rate. Methods: A comparison of the early efficacy and SAE was performed between pediatric patients treated with Chinese Children Cancer Group-ALL 2015(CCCG-ALL 2015) protocol from January 2019 to June 2020 a nd those treated with Chinese Children Leukemia Group-ALL 2008(CCLG-ALL 2008) protocol from January 2017 t o December 2018. Results: The remission rate before consolidation chemotherapy between the two groups was nots ignificantly different(P=0.198), but the negative conversion rate of minimal residual disease(MRD) in CCLG-ALL2008 group was significantly higher than that in CCCG-ALL 2015 group(P=0.000). The incidence of SAE in CCCG-ALL 2015 group was significantly lower than that in CCLG-ALL 2008 group(P=0.021), and the incidence of infection-r elated SAE was significantly higher in the latter(P=0.001), while the difference of non-infection-related SAE was nots tatistically significant(P=0.623). In addition, the treatment-related mortality in CCCG-ALL 2015 group was significantlyl ower than that in CCLG-ALL 2008 group(P=0.003). Conclusion: CCCG-ALL 2015 regimen reduces the intensity ofc hemotherapy, which can significantly decrease the chemotherapy-related SAE(especially infection-related SAE), as well as treatment-related mortality. However, the MRD negative conversion rate is low before consolidation treatment, and the overall long-term efficacy remains to be further observed.

关 键 词：急性淋巴细胞白血病 儿童 严重不良事件 疗效 

分 类 号：R733.71[医药卫生—肿瘤]